TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Dec. 4 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced that Iprad Santé
S.A. has started the commercialization in France and Belgium of Dermylex(TM)
under the Psopax(R) brand.
Psopax(R) will be officially presented during the "Journées
Dermatologiques" in Paris, an annual conference on dermatology. This
conference is an annual meeting point for French and European dermatologists
which will be held from December 4th to 8th.
Iprad Santé employs more than 105 medical representatives and
32 marketing representatives on the French and Belgium markets. Psopax(R) is
now available in all French and Belgium drugstores.
About Dermylex(TM) (Psopax(R) in France and Belgium)
Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. For more information on Dermylex(TM)
please consult the web site at www.dermylex.com.
Dermylex(TM) is also available in Canada in drugstores and in the US in
health professionals' clinics under the BioDerm brand.
About Advitech Inc. www.advitech.com
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Recently, Advitech launched Dermylex(TM) for the treatment of
About The Iprad Group: www.groupeiprad.com
Iprad Group consists of two different business units: Iprad Laboratory
develops pharmaceutical products and Iprad Santé commercializes cosmeceutical
products and food supplements for the Iprad Group. Iprad Santé S.A. employs on
the French and Belgian territories 105 medical visitors and 32 commercial
representatives. Their main products target the dermatological, gynaecological
and gastroenterology markets and they have generated, in 2006, sales of more
than 40 millions Euros. Iprad Group has experienced a strong growth over the
past ten years and it intends to maintain this growth by adding up products
specific to dermatology.
This press release contains forward-looking statements which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
email@example.com, www.advitech.com; Serge Comeau, Investor's relations, (514)